Baxter International Inc. (NYSE:BAX) Receives $22.45 Consensus Target Price from Brokerages

Shares of Baxter International Inc. (NYSE:BAX) have received a consensus rating of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $22.4545.

A number of research firms have weighed in on BAX. Wall Street Zen raised shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. TD Cowen boosted their price target on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, July 27th. Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wells Fargo & Company raised their price target on shares of Baxter International from $19.00 to $23.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Citigroup upgraded Baxter International from a “sell” rating to a “neutral” rating and raised their target price for the company from $17.00 to $28.00 in a research note on Friday, July 31st.

Baxter International Price Performance

Shares of NYSE BAX opened at $23.80 on Friday. The stock has a market capitalization of $12.31 billion, a PE ratio of -11.50, a P/E/G ratio of 3.65 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The business has a fifty day moving average price of $24.98 and a two-hundred day moving average price of $20.84. Baxter International has a fifty-two week low of $15.73 and a fifty-two week high of $30.00.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same period in the prior year, the firm posted $0.59 EPS. Baxter International’s quarterly revenue was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities analysts predict that Baxter International will post 2.04 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International’s dividend payout ratio is currently -1.93%.

Hedge Funds Weigh In On Baxter International

Hedge funds have recently bought and sold shares of the company. Basepoint Wealth LLC purchased a new stake in Baxter International during the fourth quarter worth about $26,000. Jones Financial Companies Lllp bought a new position in Baxter International in the 2nd quarter worth approximately $26,000. Imprint Wealth LLC purchased a new position in Baxter International in the 3rd quarter valued at approximately $27,000. CYBER HORNET ETFs LLC grew its stake in Baxter International by 52.4% in the 2nd quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 740 shares in the last quarter. Finally, Community Bank N.A. bought a new stake in Baxter International during the 2nd quarter valued at $46,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops and supplies medical products and technologies used in hospitals, outpatient facilities, physician offices and other care settings. Its offerings include intravenous therapy products and infusion systems, injectable medications and drug-compounding technologies, surgical products, patient-monitoring systems, respiratory-care equipment, and products used in hospital beds and connected-care environments.

The company serves healthcare providers and patients in numerous countries, with operations and customers across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.